Veolity by MeVis Medical Solutions AG Enhances Reading of Screening Chest CT Studies

Early detection of lung cancer helps save lives. In the U.S., screening programs for high-risk groups will be implemented next year; European countries are expected to follow. For imaging centers looking into offering services, medical software specialist MeVis Medical Solutions AG is offering support to help them cope with the vast number of clients, with the implementation of guidelines, and quality requirements.

Lung cancer is the leading cancer killer in both men and women in the United States and elsewhere. It causes more deaths than the next three most common cancers combined (colon, breast, and pancreatic). The prime challenge is that, in most cases, patients present when their condition is symptomatic; at that stage, treatment is difficult and outcomes are less than positive. Early detection can help save lives: results of the U.S. National Lung Screening Trial (NLST) show a 20 percent reduction in mortality thanks to CT screening. The U.S. is now turning to lung screening for high-risk groups to ameliorate this situation while European policymakers are still in the process of finding facts, based on the Dutch-Belgian "Nelson” and further trials. However, European countries are expected to follow suit.

The challenge to be met by providers of imaging services is manifold, ranging from handling enormous numbers of patients and ensuring diagnostic precision to safeguarding adherence to guidelines. Veolity, a reading platform for high-throughput environments developed by medical software specialist MeVis Medical Solutions AG in Bremen/Germany, supports radiologies in achieving these aims.

Based on leading-edge research, Veolity optimizes reading workflows. It brings together lung CAD – computer-aided detection – of solid pulmonary nodules approved by the FDA, integration and automatic registration of prior studies, and efficient, state-of-the-art reporting. Reports are generated automatically according to current standards and guidelines, and nodule malignancy prediction is added to reports. Additional features include automated measuring, integration of incidental findings, determination of patient follow-up, and integration of screening worklists.

"Reading used to be a cumbersome process full of risks”, explains Bernd Kuemmerlen, Product Manager, MeVis Medical Solutions AG. "Radiologists, who are subject to enormous workloads, need to analyze hundreds of slices to identify nodules of which there may be several in an individual case. They have to measure those nodules manually and write their report. Veolity automates most of these steps, ensuring diagnostic precision by detecting nodules, by providing objective measurements, and comparing results with prior findings. In the U.S. as well as in Europe, there is widespread interest in Veolity from organizations which prepare themselves for the launch of lung screening programs.”

About Veolity

Veolity is a reading platform for high-throughput environments. Its features include FDA-approved vendor-neutral computer-aided detection (CAD) of lung nodules, automated measuring of nodules, integration and registration of prior studies, and reporting based on standards and guidelines.

www.veolity.com

Meet MeVis Medical Solutions AG at RSNA 2014

MeVis will showcase Veolity and further solutions for radiologists at booth 2965-F, in hall A, South Building, German Pavilion.

www.rsna.org

About MeVis Medical Solutions AG

www.mevis.de

MeVis Medical Solutions AG was founded in 1997 and is one of the world’s leading independent developer and provider of medical imaging software with focus on dedicated, disease-oriented clinical applications. MeVis AG has been listed on the Frankfurt Stock Exchange in the Prime Standard segment of the Regulated Market since November 16, 2007.

Over the past few years, there has been an enormous increase in the complexity and volume of medical imaging data derived from diagnostic imaging processes such as digital mammography, computed tomography (CT), magnetic resonance imaging (MRI), and ultrasound (US). MeVis’ products analyze and process this data in such a way as to provide medical professionals with crucial information for early detection, diagnosis and intervention in the areas of cancer and lung diseases as well as neurological disorders. The Company develops its software solutions in close consultation with world's leading medical experts and original equipment manufacturers (OEM) in the medical technology sector and primarily markets this software via these partnerships.